IVBM All Coverage

Ambulatory clinical pharmacists improve patient outcomes and reduce health care costs by providing hands-on chronic disease management, patient education, and medication cost oversight, according to Caroline Vovan, PharmD, CDE.

Caroline Vovan, PharmD, CDE, highlights how ambulatory clinical pharmacists contribute to value-based care by managing chronic conditions, improving medication adherence, and reducing costs.

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.

Jody Agena, PharmD, MBA, director of pharmacy operations, Virginia Cancer Specialists, discusses the various responsibilities of the pharmacist within community oncology settings.

Eric Lander, MD, discussed the difficulty that clinicians and pharmacists face in getting insurance coverage for category 2B treatments in the National Comprehensive Cancer Network guidelines, which could affect how patients are treated for cancer.

Circulating tumor DNA (ctDNA) testing changes occur nearly every year, making consistent updates to National Comprehensive Cancer Network (NCCN) guidelines important for clinicians to make decisions on the use of these methods of testing, says Eric Lander, MD.

Patients can benefit both financially and clinically by enrolling in ongoing clinical trials, said Eric Lander, MD.

Coverage from IVBM Cleveland, held May 15, 2025.

Coverage from IVBM Princeton, held May 8, 2025.

Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, speaks about the clinical and operational priorities that academic medical centers make front-and-center when caring for underserved populations receiving treatment for cancer.

Pharmacists play a crucial role in managing treatment with chimeric antigen receptor T-cell therapy and bispecific antibodies, focusing on patient selection and side effects, explained Eileen Peng, PharmD, of Astera Cancer Care.

Meaningful transformation in health care requires ongoing, collaborative efforts, explained Eboni Price-Haywood, MD, MPH, MMM, Xavier Ochsner College of Medicine; and Toni Flowers, PhD, DHL, MBA, LCMC Health.

Eboni Price-Haywood, MD, MPH, MMM, Xavier Ochsner College of Medicine, and Toni Flowers, PhD, DHL, MBA, LCMC Health, advocate for understanding individual patient circumstances, ultimately leading to more comprehensive and effective outcomes.

"Value" in oncology should measure far more than clinical outcomes, stated Andrew Chapman, DO, as he argued how rethinking "value" could not only enhance patient care but also drive down costs.

Although immunotherapies and biomarker-driven interventions have transformed lung cancer outcomes, Martin Edelman, MD, Fox Chase Cancer Center, highlighted the present challenge hindering clinicians' abilities to anticipate patients' treatment responses.

Pierluigi Porcu, MD, speaks to the considerations clinicians need to account for to balance cost, patient experience, and outcomes for those with chronic lymphocytic leukemia (CLL).

Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.

Elizabeth Grush, MBA, speaks to the support, benefits, and holistic considerations that patient-centered care can provide for the betterment of patient experiences and outcomes.

Cathy Eng, MD, FACP, FASCO, participated on the panel discussion, “Health Equity in Cancer Care Delivery,” during the January Institute for Value-Based Medicine® event, “Elevating Value in Cancer Care: Nashville.”

Coverage from the Atlanta Regional meeting of the Institute for Value-Based Medicine.

Coverage from the Nashville Regional meeting of the Institute for Value-Based Medicine.

Kenny Cole, MD, of Ochsner Health, spoke to the value integrated teams bring to health care and the obstacles that hinder health systems' ability to move toward integrated care approaches.

Karen Winkfield, MD, PhD, addresses the importance of meeting patients where they are to expand clinical trial participation and remove barriers to trial access.

Discussions at a recent Institute for Value-Based Medicine® event highlighted the interconnected nature of cardio-kidney-metabolic disease and emphasized the need for integrated, patient-centered care.

Cardiologists, primary care physicians, and value-based care leaders convened in Phoenix, Arizona, on November 12, 2024, to share case studies and insights on how to align cardiology with the principles of value-based care, including through the application of digital tools.

Tiffany Meng, PharmD, an oncology pharmacist, UCSF Health, discusses how pharmacists help mitigate financial toxicity for patients with breast cancer.

Tiffany Meng, PharmD, an oncology pharmacist, UCSF Health, shares how pharmacists can collaborate with physicians to find the most effective and affordable therapies for patients.